Bone marrow transplantation in epidermolysis bullosa

Immunotherapy

Volumn 4, Issue 12, 2012, Pages 1859-1867

  Abdul Wahab, Alya ^a   Petrof, Gabriela ^a   McGrath, John A ^a  

^a GUY S HOSPITAL   (United Kingdom)

Author keywords

blister; cell therapy; stem cell; type VII collagen

Indexed keywords

BUSULFAN; CD150 ANTIGEN; COLLAGEN TYPE 7; CYCLOPHOSPHAMIDE; FLUDARABINE; HIGH MOBILITY GROUP B1 PROTEIN; INTERLEUKIN 10; KALININ; MELPHALAN; PLATELET DERIVED GROWTH FACTOR ALPHA RECEPTOR; T LYMPHOCYTE RECEPTOR;

BONE MARROW CELL; BONE MARROW TRANSPLANTATION; C57BL 6 MOUSE; CARDIOMYOPATHY; CLINICAL TRIAL (TOPIC); EPIDERMOLYSIS BULLOSA; GRAFT FAILURE; HEMATOPOIETIC CELL; HUMAN; KERATINOCYTE; MESENCHYMAL STROMA CELL; MORBIDITY; MORTALITY; NONHUMAN; PRIORITY JOURNAL; RECESSIVE DYSTROPHIC EPIDERMOLYSIS BULLOSA; REVIEW; SEPSIS; TISSUE REGENERATION; TISSUE REPAIR;

ANIMALS; BASEMENT MEMBRANE; BONE MARROW TRANSPLANTATION; CHILD; CLINICAL TRIALS AS TOPIC; EPIDERMOLYSIS BULLOSA; GUIDED TISSUE REGENERATION; HUMANS; SKIN;

EID: 84871239919     PISSN: 1750743X     EISSN: 17507448     Source Type: Journal    
DOI: 10.2217/imt.12.120     Document Type: Review

References (61)

1. Fine JD, Eady R, Bauer EA et al. The classification of inherited epidermolysis bullosa (EB): report of the third international consensus meeting on diagnosis and classification of EB. J. Am. Acad. Dermatol. 58(6), 931-950 (2008).
2. van den Akker PC, Nijenhuis M, Meijer G, Hofstra RM, Jonkman MF, Pasmooij AM. Natural gene therapy in dystrophic epidermolysis bullosa. Arch. Dermatol. 148(2), 213-216 (2011).
3. Bruckner-Tuderman L, Schnyder UW, Winterhalter KH, Bruckner P. Tissue form of type VII collagen from human skin and dermal fibroblasts in culture. Eur. J. Biochem. 165(3), 607-611 (1987).
4. Fine JD, Mellerio JE. Extracutaneous manifestations and complications of inherited epidermolysis bullosa: part I. Epithelial associated tissues. J. Am. Acad. Dermatol. 61(3), 367-384 (2009).
5. Fine JD, Mellerio JE. Extracutaneous manifestations and complications of inherited epidermolysis bullosa: part II. Other organs. J. Am. Acad. Dermatol. 61(3), 387-402 (2009).
6. Fine JD, Johnson LB, Weiner M, Li KP, Suchindran C. Epidermolysis bullosa and the risk of life-threatening cancers: the National EB Registry experience, 1986-2006. J. Am. Acad. Dermatol. 60(2), 203-211 (2009).
7. Frew JW, Martin LK, Nijsten T, Murrell DF. Quality of life evaluation in epidermolysis bullosa (EB) through the development of the QOLEB questionnaire: an EB-specific quality of life instrument. Br. J. Dermatol. 161(6), 1323-1330 (2009).
8. Wagner JE, Ishida-Yamamoto A, McGrath JA et al. Bone marrow transplantation for recessive dystrophic epidermolysis bullosa. NEJM 363(7), 629-639 (2010).
9. Grove JE, Bruscia E, Krause DS. Plasticity of bone marrow-derived stem cells. Stem Cells 22(4), 487-500 (2004).
10. Badiavas EV, Abedi M, Butmarc J, Falanga V, Quesenberry P. Participation of bone marrow derived cells in cutaneous wound healing. J. Cell. Physiol. 196(2), 245-250 (2003).
11. Borue X, Lee S, Grove J et al. Bone marrow-derived cells contribute to epithelial engraftment during wound healing. Am. J. Pathol. 165(5), 1767-1772 (2004).
12. Fathke C, Wilson L, Hutter J et al. Contribution of bone marrow-derived cells to skin: collagen deposition and wound repair. Stem Cells 22(5), 812-822 (2004).
13. Krause DS, Theise ND, Collector MI et al. Multi-organ, multi-lineage engraftment by a single bone marrow-derived stem cell. Cell 105(3), 369-377 (2001).
14. Brittan M, Braun KM, Reynolds LE et al. Bone marrow cells engraft within the epidermis and proliferate in vivo with no evidence of cell fusion. J. Pathol. 205(1), 1-13 (2005).
15. Korbling M, Katz RL, Khanna A et al. Hepatocytes and epithelial cells of donor origin in recipients of peripheral-blood stem cells. NEJM 346(10), 738-746 (2002).
16. Ishii G, Sangai T, Sugiyama K et al. In vivo characterization of bone marrow-derived fibroblasts recruited into fibrotic lesions. Stem Cells 23(5), 699-706 (2005).
17. Sasaki M, Abe R, Fujita Y, Ando S, Inokuma D, Shimizu H. Mesenchymal stem cells are recruited into wounded skin and contribute to wound repair by transdifferentiation into multiple skin cell type. J. Immunol. 180(4), 2581-2587 (2008).
18. Chino T, Tamai K, Yamazaki T et al. Bone marrow cell transfer into fetal circulation can ameliorate genetic skin diseases by providing fibroblasts to the skin and inducing immune tolerance. Am. J. Pathol. 173(3), 803-814 (2008).
19. Fan Q, Yee CL, Ohyama M et al. Bone marrow-derived keratinocytes are not detected in normal skin and only rarely detected in wounded skin in two different murine models. Exp. Hematol. 34(5), 672-679 (2006).
20. Tamai K, Yamazaki T, Chino T et al. PDGFRalpha-positive cells in bone marrow are mobilized by high mobility group box 1 (HMGB1) to regenerate injured epithelia. Proc. Natl Acad. Sci. USA 108(16), 6609-6614 (2011).
21. Heinonen S, Mannikko M, Klement JF, Whitaker-Menezes D, Murphy GF, Uitto J. Targeted inactivation of the type VII collagen gene (Col7a1) in mice results in severe blistering phenotype: a model for recessive dystrophic epidermolysis bullosa. J. Cell Sci. 112(Pt 21), 3641-3648 (1999).
22. Tolar J, Ishida-Yamamoto A, Riddle M et al. Amelioration of epidermolysis bullosa by transfer of wild-type bone marrow cells. Blood 113(5), 1167-1174 (2008).
23. Sands MS, Vogler C, Torrey A et al. Murine mucopolysaccharidosis type VII: long term therapeutic effects of enzyme replacement and enzyme replacement followed by bone marrow transplantation. J. Clin. Invest. 99(7), 1596-1605 (1997).
24. Hobbs JR, Hugh-Jones K, Barrett AJ et al. Reversal of clinical features of Hurler's disease and biochemical improvement after treatment by bone-marrow transplantation. Lancet 2(8249), 709-712 (1981).
25. Krivit W, Pierpont ME, Ayaz K et al. Bone-marrow transplantation in the Maroteaux-Lamy syndrome (mucopolysaccharidosis type VI). Biochemical and clinical status 24 months after transplantation. NEJM 311(25), 1606-1611 (1984).
26. Fritsch A, Loeckermann S, Kern JS et al. A hypomorphic mouse model of dystrophic epidermolysis bullosa reveals mechanisms of disease and response to fibroblast therapy. J. Clin. Invest. 118(5), 1669-1679 (2008).
27. Kern JS, Loeckermann S, Fritsch A et al. Mechanisms of fibroblast cell therapy for dystrophic epidermolysis bullosa: high stability of collagen VII favors long-term skin integrity. Mol. Ther. 17(9), 1605-1615 (2009).
28. Prockop DJ. Repair of tissues by adult stem/ progenitor cells (MSCs): controversies, myths, and changing paradigms. Mol. Ther. 17(6), 939-946 (2009).
29. Tolar J, Le Blanc K, Keating A, Blazar BR. Concise review: hitting the right spot with mesenchymal stromal cells. Stem Cells 28(8), 1446-1455 (2010).
30. Chen L, Tredget EE, Wu PY, Wu Y. Paracrine factors of mesenchymal stem cells recruit macrophages and endothelial lineage cells and enhance wound healing. PLoS ONE 3(4), e1886 (2008).
31. Nauta AJ, Fibbe WE. Immunomodulatory properties of mesenchymal stromal cells. Blood 110(10), 3499-3506 (2007).
32. Conget P, Rodriguez F, Kramer S et al. Replenishment of type VII collagen and re-epithelialization of chronically ulcerated skin after intradermal administration of allogeneic mesenchymal stromal cells in two patients with recessive dystrophic epidermolysis bullosa. Cytotherapy 12(3), 429-431 (2010).
33. Alexeev V, Uitto J, Igoucheva O. Gene expression signatures of mouse bone marrow-derived mesenchymal stem cells in the cutaneous environment and therapeutic implications for blistering skin disorder. Cytotherapy 13(1), 30-45 (2010).
34. Yancey KB, Hintner H. Non-herlitz junctional epidermolysis bullosa. Dermatol. Clin. 28(1), 67-77 (2010).
35. Laimer M, Lanschuetzer CM, Diem A, Bauer JW. Herlitz junctional epidermolysis bullosa. Dermatol. Clin. 28(1), 55-60 (2010).
36. Fujita Y, Abe R, Inokuma D et al. Bone marrow transplantation restores epidermal basement membrane protein expression and rescues epidermolysis bullosa model mice. Proc. Natl Acad. Sci. USA 107(32), 14345-14350 (2010).
37. Kopp J, Horch RE, Stachel KD et al. Hematopoietic stem cell transplantation and subsequent 80% skin exchange by grafts from the same donor in a patient with Herlitz disease. Transplantation 79(2), 255-256 (2005).
38. Tolar J, McGrath JA, Keene DR et al. Hematopoietic and mesenchymal cell transplantation after myeloablative and non-myeloablative conditioning for recessive dystrophic and junctional epidermolysis bullosa (RDEB, JEB). J. Invest. Dermatol. 132, S91-S91 (2012).
39. Straino S, Di Carlo A, Mangoni A et al. High-mobility group box 1 protein in human and murine skin: involvement in wound healing. J. Invest. Dermatol. 128(6), 1545-1553 (2008).
40. Mitola S, Belleri M, Urbinati C et al. Cutting edge: extracellular high mobility group box-1 protein is a proangiogenic cytokine. J. Immunol. 176(1), 12-15 (2006).
41. Schlueter C, Weber H, Meyer B et al. Angiogenetic signaling through hypoxia -HMGB1: an angiogenetic switch molecule. Am. J. Pathol. 166(4), 1259-1263 (2005).
42. Zimmermann K, Volkel D, Pable S et al. Native versus recombinant high-mobility group B1 proteins: functional activity in vitro. Inflammation 28(4), 221-229 (2004).
43. Takahashi K, Yamanaka S. Induction of pluripotent stem cells from mouse fibroblast cultures. Cell 126(4), 663-676 (2006).
44. Aasen T, Raya A, Barrero MJ et al. Efficient and rapid generation of induced pluripotent stem cells from human keratinocytes. Nat. Biotechnol. 26(11), 1276-1284 (2008).
45. Aasen T, Izpisua Belmonte JC. Isolation and cultivation of human keratinocytes from skin or plucked hair for the generation of induced pluripotent stem cells. Nat. Protoc. 5(2), 371-382 (2010).
46. Itoh M, Kiuru M, Cairo MS, Christiano AM. Generation of keratinocytes from normal and recessive dystrophic epidermolysis bullosa-induced pluripotent stem cells. Proc. Natl Acad. Sci. USA 108(21), 8797-8802 (2011).
47. Tolar J, Xia L, Riddle MJ et al. Induced pluripotent stem cells from individuals with recessive dystrophic epidermolysis bullosa. J. Invest. Dermatol. 131(4), 848-856 (2010).
48. Jonkman MF, Scheffer H, Stulp R et al. Revertant mosaicism in epidermolysis bullosa caused by mitotic gene conversion. Cell 88(4), 543-551 (1997).
49. Lai-Cheong JE, McGrath JA, Uitto J. Revertant mosaicism in skin: natural gene therapy. Trends Mol. Med. 17(3), 140-148 (2011).
50. Pasmooij AM, Nijenhuis M, Brander R, Jonkman MF. Natural gene therapy may occur in all patients with generalized non-herlitz junctional epidermolysis bullosa with COL17A1 mutations. J. Invest. Dermatol. 132(5), 1374-1383 (2012).
51. Liang Y, Zhang H, Feng QS et al. The propensity for tumorigenesis in human induced pluripotent stem cells is correlated with genomic instability. Chin. J. Cancer doi:10.5732/cjc.012.10065 (2012) (Epub ahead of print).
52. Titeux M, Pendaries V, Zanta-Boussif MA et al. SIN retroviral vectors expressing COL7A1 under human promoters for ex vivo gene therapy of recessive dystrophic epidermolysis bullosa. Mol. Ther. 18(8), 1509-1518 (2010).
53. Mavilio F, Pellegrini G, Ferrari S et al. Correction of junctional epidermolysis bullosa by transplantation of genetically modified epidermal stem cells. Nat. Med. 12(12), 1397-1402 (2006).
54. Wong T, Gammon L, Liu L et al. Potential of fibroblast cell therapy for recessive dystrophic epidermolysis bullosa. J. Invest. Dermatol. 128(9), 2179-2189 (2008).
55. Uitto J, Christiano AM, Mclean WH, McGrath JA. Novel molecular therapies for heritable skin disorders. J. Invest. Dermatol. 132(3 pt 2), 820-828 (2012).
56. Woodley DT, Remington J, Huang Y et al. Intravenously injected human fibroblasts home to skin wounds, deliver type VII collagen, and promote wound healing. Mol. Ther. 15(3), 628-635 (2007).
57. Goldmann T, Overlack N, Wolfrum U, Nagel-Wolfrum K. PTC124-mediated translational readthrough of a nonsense mutation causing Usher syndrome type 1C. Hum. Gene Ther. 22(5), 537-547 (2011).
58. Shiozuka M, Wagatsuma A, Kawamoto T et al. Transdermal delivery of a readthrough-inducing drug: a new approach of gentamicin administration for the treatment of nonsense mutation-mediated disorders. J. Biochem. 147(4), 463-470 (2010).
59. Woodley D, Wang X, Zhou H, Wu T, Muirhead T, Chen M. Bone marrow stem cells improve the survivability of RDEB mice but do not correct the fundamental type VII collagen defect. J. Invest. Dermatol. 128, S126 (2008).
60. Tolar J, McGrath JA, Keene DR et al. Hematopoietic and mesenchymal stem cell transplantation for recessive dystrophic and junctional epidermolysis bullosa. J. Invest. Dermatol. 131, S90-S90 (2011).
61. Kiuru M, Itoh M, Cairo MS, Christiano AM. Bone marrow stem cell therapy for recessive dystrophic epidermolysis bullosa. Dermatol. Clin. 28(2), 371-382, xii-xiii (2010).